The global veterinary pain management market is projected to reach USD 2.5 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 6.7% during the forecast period. Growth in this market is driven by factors such as the increasing animal population, increasing consumption of meat & milk, growing prevalence of diseases, and the increasing number of veterinary practitioners in developed economies. However, increasing pet care costs are expected to restrain the growth of this market to a certain extent during the forecast period.
In this report, the veterinary pain management market has been segmented on the basis of product, application type, animal, end user, and region.
To know about the assumptions considered for the study download the pdf brochure
Prominent players in the veterinary pain management market are Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (US), Elanco Animal Health Incorporated (US), Merck & Co., Inc. (US), Dechra Pharmaceuticals (UK), Vetoquinol (France), Norbrook Laboratories Limited (Ireland), Ceva Santé Animale (France), Chanelle Pharma (Ireland), K-Laser USA (US), Assisi Animal Health (US), Multi Radiance Medical (US), Avazzia (US), SOUND Technologies (US), IRM Enterprises Pvt. Ltd. (India), Ashish Life Science Pvt. Ltd. (India), Century Pharmaceuticals Ltd. (India), VETINDIA Pharmaceuticals Limited (India), Ourofino Animal Health (Brazil), SeQuent Scientific Limited (India), LABINDIA Healthcare Pvt. Ltd. (India), Morvel Laboratories Pvt. Ltd. (India), Richter Pharma AG (Austria), Zuche Pharmaceuticals Pvt. Ltd. (India), and Fidelis Animal Health (US).
Boehringer Ingelheim held the leading position in the global veterinary pain management market in 2021, accounting for a largest share. The company has a strong portfolio of pharmaceutical products that focus on the treatment of chronic diseases in companion animals. It manufactures and markets Metacam, a best-selling pain management drug used to cure osteoarthritis in companion animals. To sustain its leading position in the market, the company adopts several growth strategies such as expansions, agreements, and partnerships. In 2022, the company has collaborated with Carthronix, Inc. (US) to identify new molecules to target cancers and cancer-associated pain in dogs.
Zoetis held the second position in the global veterinary pain management market, with a second largest share in 2021. It offers best-selling pain management drugs for companion animals such as cats, dogs, and horses. It is the manufacturer and supplier of Rimadyl, a best-selling pain management drug for dogs. The company focuses on investing in R&D activities. Zoetis incurred R&D expenses of USD 508 million in 2021, USD 463 million in 2020, and USD 457 million in 2019. The company focuses on interacting directly with its customers, which gives it a competitive advantage over its peers.
Elanco Animal Health Incorporated.
Elanco held the third position in the veterinary pain management market, accounting for a third largest share in 2021. Elanco has a vast geographical presence in all major markets. It has offices and research centers at multiple locations within the Americas, Europe, the Middle East & Africa, and Asia Pacific. Elanco primarily pursues the strategy of product launches to increase its share in the veterinary pain management market. In 2022, the company received FDA approval for Zorbium, a new prescription medicine used to control post-operative pain in cats.
Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE